Alpha DaRT in Glioblastoma Keep the Denominator Intact
DRTS
Executive Summary
REGAIN reports responses in six evaluable patients. Confirmation, imaging interpretation, follow-up and financing remain central; the eight treated patients are not an eight-patient confirmed response set. BioScore unverified; no editorial investment rating assigned.
A treatment signal in recurrent glioblastoma deserves attention because the clinical need is substantial. Alpha Tau’s November 15 REGAIN disclosure reports that all six participants who had reached response assessment had a best imaging response: five complete and one partial. The data justify following the program closely. Their proper interpretation begins with the denominator and the study’s purpose. [1]
What was measured
Eight participants had been treated as of November 11. Six were evaluable for imaging response; the latest three responses still required confirmation on later scans. The trial is an open-label, single-arm feasibility and safety study intended to enroll up to 20 participants, not a randomized efficacy trial. [1,2]
All eight were alive at cutoff. Median follow-up of 6.9 months applies to the six evaluable participants. “Median survival not reached” does not supply a survival estimate that can be compared directly with historical medians. Different selection, starting points and follow-up can create apparent differences without a treatment effect.
Imaging interpretation matters especially here. Four of the six had necrosis or suspected necrosis; in two, investigators could not yet distinguish necrosis from progression. The company also describes a previously reported grade 3 serious seizure event with Todd’s paralysis. “No unanticipated serious adverse events” is not the same as no serious adverse events. [1]
The investment question is what the next study can resolve
Alpha DaRT delivers alpha-emitting sources into a tumor. Feasible placement and local imaging responses are useful development findings, but durable disease control, neurological function, survival, safety and repeatable delivery across centers remain separate questions. Approval to conduct or expand a study is not commercialization approval for glioblastoma.
For DRTS, the path to value includes trial design, regulatory requirements, manufacturing, hospital workflow and treatment capacity as well as biological activity. A small early cohort cannot support a confident revenue ramp. The company’s view that a future dataset may support a submission is an expectation, not an agreed regulatory endpoint.
Funding adds another bridge. The resources needed to obtain a more decisive answer may change future share count or contractual claims on success. An increase in project value does not automatically produce the same increase in per-share value. This note does not calculate runway or dilution without a current, fully reconciled capital table and spending plan.
What would change the judgment
Confirmed responses over time, resolution of uncertain imaging, broader enrollment and a clearly documented regulatory path would be more useful than repeating the current response percentage. Independent assessment and patient-function measures would further test whether the local signal translates into durable benefit.
The constructive case is an early technology earning a larger, more definitive test. The risk case includes loss of response, toxicity or implementation constraints as the sample grows. Both deserve room in the model. Respecting uncertainty here preserves the value of the signal without turning a feasibility study into proof of survival benefit.
Sources: [1] Alpha Tau original disclosure, November 15, 2026; cutoff November 11. [2] REGAIN registration NCT06910306. The complete conference poster and a peer-reviewed report were not obtained for this note.
Related reading: A small clinical signal and the capital needed to test it.